Advancements in the Management of R/R AML: ASH 2024 - Episode 3
Navigating Challenges in Second- and Third-Line AML Therapy
Panelists discuss how treatment goals in the second- and third-line settings for relapsed/refractory acute monocytic leukemia (R/R AML) now focus more on disease control, quality of life, and prolonging survival, and explore the most significant unmet needs in R/R AML, particularly in addressing drug resistance and optimizing therapeutic strategies.
Video content above is prompted by the following:
- Outside of cure, what are the treatment goals in the second-line and third-line setting?
- How have these goals changed based on the recent changes within the AML landscape?
- What do you see as the most significant unmet need in R/R AML?
Related Content:
